Indian stocks: Visit www.stage2stocks.com →

Phathom Pharmaceuticals, Inc.

Stage 4 · Declining · week 19

As of Oct 22, 2026, Phathom Pharmaceuticals is in Stage 4, the downtrend phase, now in week 19 (since Jun 12, 2026). It closed at $7.01, 61.2% below its 52-week high and below its 200-day average, which is falling.

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. More about the company

$7.01
-0.28% today
$567M · Small cap
Market Neutral — Building

Pro read

Pro

Our read

Declining, below its long-term trend

Setup score

—

Momentum

Steady

Edge

—

Is PHAT early, or has it already run? Pro answers that for every US stock we cover, after every close.

Get Pro · $19 a month

Renews monthly until you cancel. Cancel any time in Plan & billing.

Loading price chart…
Stage Cycle Timeline2023-08-16 → 2026-10-22
S4 16w
S2 26w
S4 25w
S2 27w
S4 19w
2023-08-162026-10-22
S1S2S3S4Setup score (0–10, dashed line at 5)
S2 5w → S3 6w → S4 16w → S1 12w → S2 26w → S3 4w → S4 25w → S1 7w → S2 27w → S3 6w → S4 7w → S1 4w → S4 19w current
Total tracked: 165 weeks across 13 stage runs.

PHAT among Biotechnology349th of 591 by relative strength

All 591 →
Stocks in Biotechnology ranked by relative strength, with stage and one-month change
#StockStageRS1M
1GTBPStage 2 · wk 799−22.3%
2IOVAStage 2 · wk 1899+38.8%
3SLSStage 3 · wk 499−1.5%
4MRNAStage 2 · wk 1799+11.3%
5TWSTStage 2 · wk 3999−14.5%
6KODStage 2 · wk 499+172.1%
7ERASStage 3 · wk 599+0.7%
8CLYMStage 3 · wk 399−15.8%
…349PHATStage 4 · wk 1924+0.4%
vs 52W High
-61.2%
$6.70 lo$18.08 hi
61.2% below 52W high, deep Stage 4 damage
In Stage 4, distance from the 52-week high reflects an ongoing decline, not a discount.
Stage Maturity
Week 19
1w13w26w
Week 19, established downtrend
How long this stock has been in Stage 4 decline. The longer the downtrend, the more entrenched the selling pressure. No length of decline marks a bottom on its own.
vs 200 DMA
-34.7%
200 DMA: $10.73 · sloping down
In Stage 4, the stock is below its 200-day average, the hallmark of a downtrend. Stage analysis waits for that to reverse before buying.
Rel Volume
0.66x
vs 50-day avg
High volume on down days in Stage 4 confirms institutional selling. Low-volume bounces are typical. They lack real buyers and are easy to mistake for reversals.
Trend Health
↓
Short-term trend rolling over
Two reads of momentum. The arrow shows the direction of the short-term trend: rising (↑ or ↗), flat (→) or rolling over (↓). The ⇈ mark appears when our trend model reads the move as gaining speed on top of the longer trend. Strongest when both agree.
1M
+0.4%
3M
-38.7%
6M
-42.4%
YTD
-55.4%
1Y
-49.9%
Scan Membership
Breakout Watch
Latest: 2024-05-20
6 appearances in last 60 days. First seen: 2020-09-28.
A stock that keeps qualifying week after week does so because its Stage 2 structure keeps holding. Staying power in the scan says more about the trend than any single appearance.
Recent Stage Timeline
2026-10-22S4
Wk 19 · Vol 0.66x
2026-10-21S4
Wk 19 · Vol 0.54x
2026-10-20S4
Wk 18 · Vol 0.57x
2026-10-19S4
Wk 18 · Vol 0.78x
2026-10-16S4
Wk 18 · Vol 0.96x
2026-10-15S4
Wk 18 · Vol 0.92x
2026-10-14S4
Wk 18 · Vol 1.30x
2026-10-13S4
Wk 17 · Vol 1.48x
2026-10-12S4
Wk 17 · Vol 0.74x
2026-10-09S4
Wk 17 · Vol 0.62x
2026-10-08S4
Wk 17 · Vol 0.90x
2026-10-07S4
Wk 17 · Vol 1.11x
Moving averages & range
50 DMA
$8.03
200 DMA
$10.73
52W High
$18.08
52W Low
$6.70
5D Low
$6.92
Resistance levels (recent highs)
20d High
$7.50
60d High
$9.58
120d High
$13.05
250d High
$18.08
Next resistance
+7.0%
to 20d High
Dividend Yield
0.00%
P/B -1.6

Phathom Pharmaceuticals: quick answers

What stage is Phathom Pharmaceuticals in?

As of Oct 22, 2026, Phathom Pharmaceuticals (PHAT) is in Stage 4, the downtrend phase. It entered Stage 4 on Jun 12, 2026 and is in week 19. What the four stages mean

Is Phathom Pharmaceuticals in an uptrend?

No. Phathom Pharmaceuticals is in a Stage 4 downtrend. It trades 34.7% below its 200-day average, which is falling.

How far is Phathom Pharmaceuticals from its 52-week high?

Phathom Pharmaceuticals closed at $7.01 on Oct 22, 2026, 61.2% below its 52-week high of $18.08. Its 52-week low is $6.70.

How has Phathom Pharmaceuticals performed over the past year?

As of Oct 22, 2026, Phathom Pharmaceuticals is down 49.9% over the past year and down 55.4% so far in 2026.

Which sector and industry is Phathom Pharmaceuticals in?

Phathom Pharmaceuticals is in the Biotechnology industry, part of the Health Care sector.

About this companyHealth Care· Biotechnology

Phathom Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases in the United States. It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.

Visit company website →

All analytics based on EOD data. Data as of 2026-10-22. Past data patterns are not indicative of future results. This page is a data analytics tool only.